Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Recent Articles By The Author
Big-Game Hunting for My Next 10-Bagger
It's every investor's dream to find a stock that goes up at least 1,000%; here are a few that did.
Strategies for 3 Biotechs Before FDA Action
Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.
Latest Reasons to Avoid Alzheimer's Plays
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector
I continue to see these names as bargains in the biotech and biopharma space.
Insiders Are Buying These 2 Stocks Now
Here are a couple of names that have piqued my curiosity over the past few weeks.
ASCO's Big Winner: Loxo Oncology
Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
How to Manage Risk in Biotech Stocks
T2 Biosystems' recent run-up on a positive event provides an important lesson for biotech investors.
Two Antibiotic Plays
They may not get all the attention, but antibiotic drugs are increasingly important.
How to Manage Risk in Biotech
T2 Biosystems used the run-up on a positive event - an FDA approval - to raise additional capital.